Market closedNon-fractional

Sage Therapeutics/SAGE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Sage Therapeutics

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Ticker

SAGE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

487

SAGE Metrics

BasicAdvanced
$639M
Market cap
-
P/E ratio
-$8.39
EPS
0.92
Beta
-
Dividend rate
$639M
0.92
12.224
11.772
0.468
-31.98%
-54.72%
6.992
0.91
0.91
-1.498
868.96%
-10.49%
-56.59%
-10.38%

What the Analysts think about SAGE

Analyst Ratings

Majority rating from 22 analysts.
Hold

SAGE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,372.15% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.9M
-89.86%
Net income
-$108M
231.50%
Profit margin
-1,372.15%
3,169.36%

SAGE Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 9.28%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.68
-$3.37
-$0.55
-$1.80
-
Expected
-$2.55
-$2.73
-$1.28
-$1.65
-$1.66
Surprise
4.95%
23.42%
-56.94%
9.28%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Sage Therapeutics stock?

Sage Therapeutics (SAGE) has a market cap of $639M as of July 05, 2024.

What is the P/E ratio for Sage Therapeutics stock?

The price to earnings (P/E) ratio for Sage Therapeutics (SAGE) stock is 0 as of July 05, 2024.

Does Sage Therapeutics stock pay dividends?

No, Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Sage Therapeutics dividend payment date?

Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders.

What is the beta indicator for Sage Therapeutics?

Sage Therapeutics (SAGE) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Sage Therapeutics stock

Buy or sell Sage Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing